Evidence map›Paper›PMID 38540999›Full record

ArticleJournal of personalized medicine2024

Genome Sequencing of Multiple Primary Lung Cancers Harbouring Mixed Histology and Spontaneously Regressing Small-Cell Lung Cancer.

Valentina Thomas, Ahmed Rashed, Clare Faul, Siobhan Nicholson, Vincent Young, John Hanson, Bryan T Hennessy, Sinead Toomey, Simon J Furney

Open access · goldAbstract readCase Reports
In one paragraph

Article in Journal of personalized medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Valentina ThomasGenomic Oncology Research Group, Department of Physiology and Medical Physics, RCSI University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.
Ahmed RashedOur Lady of Lourdes Hospital, A92 VW28 Drogheda, Ireland.
Clare FaulSt Luke's Radiation Oncology Network, D08 E797 Dublin, Ireland.
Siobhan NicholsonDepartment of Histopathology, St James's Hospital, D08 E797 Dublin, Ireland.
Vincent YoungDepartment of Cardiothoracic Surgery, St James's Hospital, D08 E797 Dublin, Ireland.
John HansonOur Lady of Lourdes Hospital, A92 VW28 Drogheda, Ireland.
Bryan T HennessyOur Lady of Lourdes Hospital, A92 VW28 Drogheda, Ireland.
Sinead ToomeyMedical Oncology Group, Department of Molecular Medicine, RCSI University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.
Simon J FurneyGenomic Oncology Research Group, Department of Physiology and Medical Physics, RCSI University of Medicine and Health Sciences, D02 YN77 Dublin, Ireland.ORCID 0000-0002-8920-6800
Our Lady of Lourdes Hospital · IESt. James's Hospital · IEMolecular Medicine Ireland · IE

Funding

Wellcome Trust
6 · The paper itself

Abstract

Up to 15% of lung cancer patients present two or more anatomically separate primary lung lesions, known as multiple primary lung cancers (MPLCs). While surgical resection or stereotactic body radiation therapy (SBRT) is the standard of care for most early-stage lung cancer cases, this may not be an option for patients with widespread tumours, highlighting the need for the improved targeted management of MPLC patients, which remains challenging. Moreover, the spontaneous regression (SR) of small-cell lung cancer (SCLC) is rare, with only four cases accounted for between 1988 and 2018. We report a rare MPLC case harbouring the mixed histology of non-small-cell lung cancer adenocarcinoma (NSCLCa) and SCLC and the SR of SCLC without treatment. The patient was diagnosed in 2015 with MPLCs, identified as NSCLCa and SCLC. In 2016, a restaging PET/CT scan prior to the start of treatment showed SCLC SR. In 2018, a further tumour was detected in the patient's mandible, and a re-biopsy of the SCLC revealed histology consistent with NSCLCa. Whole-genome sequencing (WGS) analysis identified a high expression of programmed death ligand-1 (PDL-1) in the NSCLCa, which was treated with pembrolizumab. WGS revealed distinct genomic profiles and mutational mechanisms in MPLCs, suggesting the need for distinct targeted therapies to improve the management of MPLC patients and highlighting the importance of precision evaluation.

Indexed as

genomicsnon-small-cell lung cancersmall-cell lung cancerspontaneous regressionsynchronous cancerswhole genome sequencing

Identifiers

PMID38540999
PMCPMC10971334
OpenAlexW4392238557

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.